Re: What's the deal with Zenith?
in response to
by
posted on
Jun 23, 2023 02:15AM
Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials
Oh how could I forget. For the costs, in addition to the ones I've pointed in the previous post you would also have to add in the $6 million loan to Hepalink plus 2 years of unpaid interest which I think is in US$ and whatever we owe Eversana.
That $40 million KK2 is taliking about may be in the distant rear view mirror.
tada